CSIMarket
 


Akouos inc   (AKUS)
Other Ticker:  
 

Cumulative Akouos Inc 's Working Capital Ratio for Trailing Twelve Months Period

AKUS's Working Capital Ratio for Trailing Twelve Months Period and Current Assets, Current Liabilities growth


Select the Comparisons : Select the Ratio:

AKUS Working Capital Ratio for Trailing Twelve Months Period

(Sep 30 2022)
III. Quarter
(Jun 30 2022)
II. Quarter
(Mar 31 2022)
III. Quarter
(Dec 31 2021)
IV. Quarter
(Sep 30 2021)
III. Quarter
Y / Y Current Liabilities Growth -23.09 % 20.77 % 162.99 % 56.89 % -
Y / Y Current Assets Growth -31.44 % -28.87 % -27.35 % -23.97 % -
Working Capital Ratio for Trailing Twelve Months Period 13.61 14.22 16.12 21.52 26.31
Total Ranking # 289 # 371 # 323 # 227 # 134
Seq. Current Liabilities Growth -30.86 % -21.39 % 10.46 % 28.1 % 8.57 %
Seq. Current Assets Growth -10.48 % -7.82 % -10.46 % -7.21 % -7.13 %


Working Capital Ratio for Trailing Twelve Months Period Comment for 12 Months ending at Sep 30 2022
On the trailing twelve months basis Despite year on year decrease in Akouos Inc 's average Current Liabilities to $10 millions, Working Capital Ratio for Trailing Twelve Months Period to 13.61 below company average Working Capital Ratio for Trailing Twelve Months Period.
Working Capital Ratio for Trailing Twelve Months Period is the average cumulative value over the last four quarters.

Among companies operatig within Major Pharmaceutical Preparations industry 74 other companies have achieved higher Working Capital Ratio for Trailing Twelve Months Period than Akouos Inc . While overall ranking remained unchanged compare to previous quarter at no. .

What is Working Capital Ratio?
More about AKUS
Working Capital Ratio AKUS in the most recent quarter
Working Capital Ratio for Trailing Twelve Months Period Company Ranking
Within: No.
Industry # 75
Sector # 116
S&P 500 # 196


Working Capital Ratio for Trailing Twelve Months Period Statistics
High Average Low
29.25 20.17 13.61
(Jun 30 2021)   (Sep 30 2022)




Companies with similar average Working Capital Ratio for Trailing Twelve Months Period for 12 months ending Sep 30 2022, within Major Pharmaceutical Preparations Industry Working Capital Ratio for Trailing Twelve Months Period
Aerovate Therapeutics Inc   36.78 
Infinity Pharmaceuticals Inc   35.89 
Artelo Biosciences Inc   35.70 
Theseus Pharmaceuticals Inc   34.95 
Cocrystal Pharma Inc   33.60 
Nextcure Inc   32.81 
Stoke Therapeutics Inc   32.10 
Eqrx Inc   31.83 
Rezolute Inc   30.44 
Nanoviricides inc   30.30 
Day One Biopharmaceuticals Inc   30.05 
Immix Biopharma Inc   29.94 
Synaptogenix Inc   28.93 
Xortx Therapeutics Inc   28.78 
Nuvalent Inc   28.46 
Kezar Life Sciences Inc   28.23 
Diamedica Therapeutics Inc   28.02 
Edgewise Therapeutics inc   26.97 
Merrimack Pharmaceuticals Inc  26.97 
Spruce Biosciences Inc   26.94 
Janux Therapeutics Inc   26.91 
Karuna Therapeutics Inc   26.74 
Pmv Pharmaceuticals Inc   26.51 
Immuneering Corporation  26.41 
Disc Medicine Inc   26.21 
An2 Therapeutics Inc   26.12 
Dice Therapeutics Inc   25.72 
Anaptysbio Inc   25.17 
Olema Pharmaceuticals inc   24.94 
Cyteir Therapeutics Inc   24.67 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com